From Classroom to Clinic: Nuwellis's Bid to Reshape Cardiac Care

MINNEAPOLIS, MN – June 18, 2026 – In a specialized training room at the University of Minnesota, the future of critical cardiac care was getting a hands-on demonstration. Over 280 physicians—a mix of seasoned intensivists and cardiology fellows on the front lines of medicine—gathered to learn the mechanics of the Aquadex SmartFlow® system, a medical device designed to manage one of the most persistent and dangerous conditions in critically ill patients: fluid overload.

The training, a cornerstone of the 4th annual Critical Care Cardiology Education Summit (CCCES), was organized by Nuwellis, Inc., the Minneapolis-based company behind the technology. This event wasn't just another conference booth; it was one of the largest, most concentrated educational initiatives for Aquadex ever conducted. It represents a critical intersection of innovation, education, and market strategy, where the adoption of a life-saving technology hinges not just on its clinical efficacy, but on the confidence of the clinicians who will use it.

"CCCES is uniquely designed to provide experiential learning and hands-on skills training for clinicians managing some of the most complex patients in cardiovascular medicine," said Nuwellis’ CEO John Erb in a recent statement. "The event was an important opportunity for us to introduce Aquadex to many fellows and practicing physicians and demonstrate how precise fluid management can play an important role in caring for critically ill patients."

The Silent Crisis of Fluid Overload

For patients in the cardiac intensive care unit (ICU), the body's delicate fluid balance can quickly become a life-or-death struggle. Conditions like heart failure or complications from major surgery can lead to fluid overload, or hypervolemia, where the body retains excess water and salt. This puts immense strain on an already weakened heart and can cause cascading organ failure, particularly in the kidneys, creating a vicious cycle known as cardiorenal syndrome.

Fluid overload is a pervasive and insidious problem. Studies have shown it is an independent predictor of higher mortality rates in ICU patients. For children recovering from cardiac surgery, higher levels of fluid overload are directly linked to increased mortality and complications. The standard first-line treatment, diuretic medication, often fails. Many critically ill patients develop diuretic resistance, leaving clinicians with limited options as their patients' conditions worsen.

"You're in a race against time," explained one critical care specialist familiar with the challenge. "When diuretics stop working, the fluid keeps accumulating. It fills the lungs, stresses the heart, and harms the kidneys. You need a way to get that fluid off safely and predictably, but the traditional methods can be blunt instruments." This is the clinical gap that technologies like Aquadex aim to fill.

A Precision Tool for a Delicate Balance

The Aquadex SmartFlow system is a form of ultrafiltration—a process that removes excess fluid directly from the blood. While similar in principle to dialysis, it is a much simpler, more targeted therapy. The system gently circulates a small amount of the patient's blood (about 35 mL) through a filter, removing a precise amount of water and salt without significantly impacting blood pressure or electrolyte levels.

Its key advantage is control. Clinicians can set and adjust the rate of fluid removal with remarkable precision. A recent software update allows for adjustments as fine as 5 mL per hour, a crucial feature when treating pediatric patients, for whom even small fluid shifts can be dangerous. Nuwellis is actively pursuing an expanded FDA label to officially include patients weighing as little as 5 kilograms (about 11 pounds), which would open a vital new avenue for pediatric care.

Clinical data suggests the approach is effective. A 2025 study in JACC: Heart Failure found that patients treated with Aquadex had a 60% reduction in heart failure events 30 days post-treatment compared to standard care. By offering a reliable alternative for diuretic-resistant patients, the technology has the potential to reduce costly hospital readmissions and, most importantly, improve patient outcomes.

The Strategy of Education

Developing an innovative device is only half the battle; driving its adoption is the other. For a technology like Aquadex, which intervenes in high-stakes critical care scenarios, physician confidence is paramount. Nuwellis's intensive training initiative at the University of Minnesota's CCCES is a direct acknowledgment of this reality. By moving beyond slide decks and into hands-on sessions, the company is embedding its technology into the practical skill set of the very people who make treatment decisions.

Partnering with a prestigious institution like the University of Minnesota, a leader in critical care education, lends significant credibility to the effort. The summit attracts a national audience of specialists, creating a powerful ripple effect as attendees return to their respective hospitals. By training not just practicing physicians but also fellows—the next generation of intensivists—Nuwellis is playing a long game, aiming to make Aquadex a standard tool in the critical care playbook for years to come. This focus on experiential learning is a core component of modern medical education, ensuring that complex innovations are translated safely and effectively from the lab to the bedside.

A High-Stakes Bet on the Future

This strategic push into education comes at a pivotal moment for Nuwellis. While the company reported a 26% year-over-year revenue increase in the first quarter of 2026, it has a history of net losses and faces significant financial headwinds, with its stock price declining sharply over the past year. The company recently raised approximately $6 million through a public offering to shore up its finances and is undergoing a leadership transition, with Mike McCormick set to take over as CEO at the end of this month.

Seen in this context, the investment in large-scale physician training is not just a marketing effort—it's a high-stakes bet on adoption driving commercial success. The company's future depends on its ability to convert clinical promise into consistent sales and expand its market share. This requires overcoming the natural inertia of hospital procurement and practice patterns, a challenge that hands-on training is uniquely suited to address.

The path for medical device companies is rarely smooth. Nuwellis itself has navigated challenges, including a serious FDA recall in March 2025 related to a component of the Aquadex system's blood circuit. Such events underscore the immense responsibility that comes with innovating in the medical field. By focusing on robust education and direct engagement with clinicians, Nuwellis is not only building a market for its product but also reinforcing the ecosystem of safety and expertise required for any new technology to truly transform patient care.